Labcorp Holdings (LH) is in focus after announcing a new alliance with the National Association of Community Health Centers. The partnership centers on leadership development and practice improvement across the Community Health Center network.

Alongside this new community health partnership, Labcorp Holdings has seen building momentum in its stock, with a 30 day share price return of 17.39% and a 1 year total shareholder return of 20.08%, supporting a 3 year total shareholder return of 58.86%.

If this kind of healthcare focused story interests you, it may be worth widening your search to see what else is moving in 42 healthcare AI stocks

After a near 30% move over three months and fresh attention on Labcorp Holdings following the NACHC alliance, the stock is already pricing in a lot of optimism. The key question is whether the current valuation still leaves enough potential upside to justify the risk.

Most Popular Narrative: 2% Undervalued

Labcorp Holdings last closed at $330.44, compared with a widely followed fair value estimate of $337.75 that reflects detailed long term forecasts and assumptions.

The introduction of new tests in oncology, women's health, autoimmune disease, and neurology is anticipated to capture more test volume and outpace growth in the broader market, positively impacting revenue and earnings. The use of AI and technology innovations is enhancing operational efficiencies, improving margins through platforms like eClaim Assist and Labcorp Diagnostic Assistant.

Curious what kind of growth profile justifies this fair value for Labcorp Holdings? The narrative leans on higher margins, rising earnings, and a lower future earnings multiple. The exact mix of assumptions may surprise you.

Result: Fair Value of $337.75 (UNDERVALUED)

However, you still need to factor in risks such as potential PAMA related reimbursement cuts, as well as tariff or regulatory changes that could pressure Labcorp Holdings margins.

Another View On Labcorp Holdings Valuation

The fair value narrative for Labcorp Holdings points to slight undervaluation at $337.75, yet the current P/E of 26.7x tells a different story. It is higher than both the US Healthcare industry at 25x and the peer average at 25x, and also above a fair ratio of 26.1x.

That gap suggests the stock is carrying some valuation risk rather than offering a clear discount. The question is whether the recent earnings momentum and oncology expansion are enough for you to stay comfortable paying a premium multiple.

Next Steps

The mix of optimism and concern around Labcorp Holdings is clear, so it makes sense to move quickly and review the detail for yourself. You can weigh both sides of the story in our breakdown of 2 key rewards and 1 important warning sign

Looking for more investment ideas beyond Labcorp Holdings?

Do not stop with Labcorp Holdings. The next opportunity you are glad you found could be sitting in plain sight, and you do not want to overlook it.

• Target resilient growth by scanning companies with support from the screener containing 20 high quality undiscovered gems.
• Prioritise sleep at night potential and focus on stability through the 78 resilient stocks with low risk scores.
• Aim for quality at a reasonable price by checking stocks filtered in the 52 high quality undervalued stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.